Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decrease in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 21,126 shares, a decrease of 67.6% from the January 29th total of 65,207 shares. Based on an average daily trading volume, of 155,980 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.9% of the company’s shares are sold short. Currently, 0.9% of the company’s shares are sold short. Based on an average daily trading volume, of 155,980 shares, the days-to-cover ratio is currently 0.1 days.

Virax Biolabs Group Price Performance

VRAX opened at $0.22 on Friday. Virax Biolabs Group has a 12-month low of $0.20 and a 12-month high of $1.85. The business’s fifty day simple moving average is $0.29 and its 200-day simple moving average is $0.48.

Virax Biolabs Group (NASDAQ:VRAX) last released its quarterly earnings data on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The company had revenue of $0.00 million for the quarter.

Analyst Ratings Changes

Several brokerages have commented on VRAX. Zacks Research raised Virax Biolabs Group to a “hold” rating in a research report on Tuesday, January 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Virax Biolabs Group in a report on Friday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $1.00 price target (down from $3.00) on shares of Virax Biolabs Group in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Virax Biolabs Group currently has an average rating of “Hold” and an average price target of $1.00.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.